Scientists may have solved weight regain problem from GLP-1 drugs

Key Points:

• Researchers have developed a minimally invasive procedure called duodenal mucosal resurfacing (DMR) that may help maintain weight loss after stopping GLP-1 medications like Ozempic and semaglutide by renewing the lining of the upper small intestine to "reset" metabolism.
• In a clinical trial with 45 patients who had lost weight using tirzepatide, those who underwent DMR regained only about 7 pounds six months after stopping the drug, maintaining over 80% of their weight loss, compared to a 14-pound regain in the control group.
• The procedure targets the duodenum to restore hormone signaling impaired by high-fat, high-sugar diets, promoting healthy tissue regrowth and improved metabolic regulation, with no serious complications and quick recovery reported.
• A larger ongoing trial, REMAIN-1, with over 300 participants is expected to report results in late 2026; if successful, DMR could offer a critical solution for sustaining weight loss after discontinuing GLP-1 drugs.
• Currently investigational and not FDA-approved, DMR addresses a significant unmet need as nearly 70% of patients regain weight after stopping GLP-1 medications due to cost, side effects, and reluctance to use drugs indefinitely.